01 junio 2011

JACC: CARDIOVASCULAR INTERVENTIONS. Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease as Culprit Lesion in Patients With Acute Myocardial Infarction

Alessandro Pappalardo, MD, Mamas A. Mamas, MD, Fabrizio Imola, MD, Vito Ramazzotti, MD, Alessandro Manzoli, MD, Francesco Prati, MD, Magdi El-Omar, MD

Objectives: This study sought to evaluate short- and long-term outcomes of patients undergoing emergency percutaneous coronary intervention (PCI) for acute myocardial infarction due to a culprit lesion in an unprotected left main coronary artery. JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 6, 2011. Copyright © 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00. PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.02.016.

01 junio 2011

JACC. Late Status of Fontan Patients With Persistent Surgical Fenestration

Andrew M. Atz, MD, Thomas G. Travison, PhD, Brian W. McCrindle, MD, MPH, Lynn Mahony, MD, Michael Quartermain, MD, Richard V. Williams, MD, Roger E. Breitbart, MD, Minmin Lu, MS, Elizabeth Radojewski, RN, Renee Margossian, MD, Wesley Covitz, MD, Welton M. Gersony, MD Pediatric Heart Network Investigators

Objectives: This study was undertaken to determine the effects of creating a systemic-to-pulmonary venous atrial-level communication (fenestration) at the time of the Fontan procedure on late outcomes. Background: Fenestrations are frequently performed during Fontan procedures, but late consequences are not well described. Journal of the American College of Cardiology Vol. 57, No. 24, 2011. Copyright © 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00. Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.031.

01 enero 2012

PROGRESS IN PEDIATRIC CARDIOLOGY. Sustainable cardiac services From the catheterization laboratory to the operating room and beyond

Forbes McGain, Nicholas R. Cox , Serina S. Cecchin , Scott McAlister , Paul R. Barach

Economic and environmental sustainability are essential to maintaining delivery of high quality healthcare. Numerous medical innovations in recent times demonstrate that modern cardiovascular care is in quick and constant flux. Examples are the novel minimally-invasive interventions, improved disease management in heart failure, innovative methods in atrial fibrillation ablation or the personalized medicine approach in cardiomyopathies. Progress in Pediatric Cardiology Volume 33, Issue 1 , Pages 81-84, January 2012. Crown Copyright © 2011 Published by Elsevier Ireland Ltd. All rights reserved.

01 junio 2011

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Atrioventricular Conduction Disturbance Characterization in Transcatheter Aortic Valve Implantation With the CoreValve Prosthesis

José M. Rubín, MD, PhD, Pablo Avanzas, MD, PhD, FESC, Raquel del Valle, MD, Alfredo Renilla, MD, Enrique Ríos, MD, David Calvo, MD, PhD, Iñigo Lozano, MD, PhD, FESC, FACC, Ignasi Anguera, MD, Beatriz Díaz-Molina, MD, Angel Cequier, MD, PhD, FESC and César Morís de la Tassa, MD, PhD, FESC

Background—Atrioventricular (AV) block is one of the most frequent complications of CoreValve transcatheter aortic valve implantation (TAVI). The aim of this study was to analyze the effects of CoreValve implantation on AV conduction. Circulation: Cardiovascular Interventions. 2011; 4: 280-286 Published online before print May 3, 2011, doi: 10.1161. Copyright © American Heart Association. All rights reserved.

01 febrero 2012

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Creating biodegradable-polymer drug-eluting stents: Shortening the duration of polymer and dual antiplatelet therapy while lengthening the follow-up

Ahmed Abdel-Latif MD, MSPH and David J. Moliterno MD

The field of percutaneous coronary intervention (PCI) has gone through major revolutions over the last two decades, and presently drug-eluting stents (DES) represent the best of what real-world practice has to offer. DES have reduced major adverse cardiac event rates (MACE) near exclusively by reducing the rates of repeat target vessel revascularization (TVR) [1]. However, the delayed endothelialization associated with DES has lead to increased rates of late stent thrombosis (ST), particularly with first-generation DES and in complex lesion subsets [2]. The etiology behind ST is multifactorial with the possibility that the durable polymer used to hold and release the antiproliferative drug results in chronic arterial wall inflammation and neoatherosclerosis. Therefore, there is growing interest in designing stents with biodegradable-polymers that may overcome this potential shortcoming of durable-polymer DES. Catheterization and Cardiovascular Interventions. Volume 79, Issue 2, pages 217–218, 1 February 2012. Article first published online: 23 JAN 2012 DOI: 10.1002/ccd.24294 Copyright © 2012 Wiley Periodicals, Inc.

01 junio 2011

JACC: CARDIOVASCULAR INTERVENTIONS. Primary Percutaneous Coronary Intervention for Unprotected Left Main Disease in Patients With Acute ST-Segment Elevation Myocardial Infarction

Giovanni B. Pedrazzini, MD, Dragana Radovanovic, MD, Giuseppe Vassalli, MD, Daniel Sürder, MD, Tiziano Moccetti, MD, Franz Eberli, MD, Philip Urban, MD, Stephan Windecker, MD, Hans Rickli, MD, Paul Erne, MD AMIS Plus Investigators

Objectives: This study sought to assess outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI) for unprotected left main (LM) disease. Background: Limited data are available on outcomes in patients with ST-segment elevation myocardial infarction undergoing LM PCI. JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 6, 2011. Copyright © 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00. PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.04.004.

01 junio 2011

CIRCULATION. Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial

Lorenz Räber, MD; Lea Wohlwend, BA; Mathias Wigger, BA; Mario Togni, MD; Simon Wandel, MSc, PhD; Peter Wenaweser, MD; Stéphane Cook, MD; Aris Moschovitis, MD; Rolf Vogel, MD, PhD; Bindu Kalesan, MSc; Christian Seiler, MD; Franz Eberli, MD; Thomas F. Lüscher, MD; Bernhard Meier, MD; Peter Jüni, MD; Stephan Windecker, MD

Background—Long-term comparative data of first-generation drug-eluting stents are scarce. We investigated clinical and angiographic outcomes of sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) at 5 years as part of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) LATE study. Circulation. 2011; 123: 2819-2828 Published online before print June 6, 2011, doi: 10.1161. Copyright © 2011 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539.

01 junio 2011

CIRCULATION. Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions

Tullio Palmerini, MD; Roxana Mehran, MD; George Dangas, MD; Eugenia Nikolsky, MD; Bernhard Witzenbichler, MD; Giulio Guagliumi, MD; Darius Dudek, MD; Philippe Genereux, MD; Adriano Caixeta, MD; LeRoy Rabbani, MD; Giora Weisz, MD; Helen Parise, ScD; Martin Fahy, MSc; Ke Xu, PhD; Bruce Brodie, MD; Alexandra Lansky, MD; Gregg W. Stone, MD

Background—The relationship between white blood cell count (WBCc) and mortality in patients with ST-segment–elevation acute myocardial infarction treated with percutaneous coronary intervention is poorly understood. Furthermore, whether there is a relationship between WBCc and risk of noncardiac mortality and bleeding after percutaneous coronary intervention is unknown. 2011; 123: 2829-2837 Published online before print May 31, 2011, doi: 10.1161. Copyright © 2011 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539.

01 junio 2011

JACC. Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents

Gregg W. Stone, MD, Ali Rizvi, MD, Krishnankutty Sudhir, MD, PhD, William Newman, MD, Robert J. Applegate, MD, Louis A. Cannon, MD, James T. Maddux, MD, Donald E. Cutlip, MD, Charles A. Simonton, MD, Poornima Sood, MD, Dean J. Kereiakes, MD SPIRIT IV Investigators

Objectives: We sought to determine whether the differences in outcomes present between everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES) in the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial at 1 year were sustained with longer-term follow-up. Background: In the SPIRIT IV trial, patients undergoing percutaneous coronary intervention who were randomized to EES compared with PES experienced lower 1-year rates of target lesion failure (cardiac death, target vessel myocardial infarction [MI], or ischemia-driven target lesion revascularization [TLR]), with significant reductions in the individual rates of MI, TLR, and stent thrombosis. Journal of the American College of Cardiology Vol. 58, No. 1, 2011. Copyright © 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00. Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.022.

01 enero 2012

PROGRESS IN PEDIATRIC CARDIOLOGY. The role of information in ensuring quality and patient safety

Martin J. Elliott

The opinions in this paper were originally requested by The Mid-Staffordshire Public Inquiry in the United Kingdom.1 This inquiry has highlighted the way in which Boards of Hospitals may fail to use information correctly in several ways; inappropriate collection, poor validation, lack of appropriate analysis and the absence of transparency. Here I outline some personal opinions based on long experience at the coal-face of both medicine and information management. Whilst many of the examples I have chosen reflect life the in the UK National Health Service, they are widely applicable internationally. Progress in Pediatric Cardiology Volume 33, Issue 1 , Pages 5-10, January 2012. Copyright © 2011 Published by Elsevier Ireland Ltd. All rights reserved.

01 junio 2011

JACC: CARDIOVASCULAR INTERVENTIONS. Clinical and Angiographic Predictors and Prognostic Value of Failed Thrombus Aspiration in Primary Percutaneous Coronary Intervention

Maarten A. Vink, MD, Miranda C. Kramer, MD, Xiaofei Li, MD, Peter Damman, MD, Saskia Z. Rittersma, MD, PhD, Karel T. Koch, MD, PhD, Allard C. van der Wal, MD, PhD, Jan G.P. Tijssen, PhD, Robbert J. de Winter, MD, PhD

Objectives: This study sought to investigate which factors are associated with failure of thrombus aspiration (TA) and if this has prognostic implications. Background: The pathophysiological mechanism and clinical benefit of TA during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction is still in debate. JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 6, 2011. Copyright © 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00. PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.03.009.

11 abril 2011

JACC. Clinical Outcomes After Transcatheter Aortic Valve Replacement Using Valve Academic Research Consortium Definitions

Philippe Généreux, MD, Stuart J. Head, MSC, Nicolas M. Van Mieghem, MD, Susheel Kodali, MD, Ajay J. Kirtane, MD, SM, Ke Xu, P HD, Craig Smith, MD, Patrick W. Serruys, MD, P HD, A. Pieter Kappetein, MD, PHD, Martin B. Leon, MD

This study sought to perform a weighted meta-analysis to determine the rates of major outcomes after transcatheter aortic valve replacement (TAVR) using Valve Academic Research Consortium (VARC) definitions and to evaluate their current use in the literature. Journal of the American College of Cardiology Vol. 59, No. 25, 2012. Copyright © 2012 by the American College of Cardiology Foundation ISSN 0735-1097. Published by Elsevier Inc.

12 enero 2012

EUROPEAN HEART JOURNAL. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis

Gian Paolo Ussia, Marco Barbanti, Anna Sonia Petronio, Giuseppe Tarantini, Federica Ettori, Antonio Colombo, Roberto Violini, Angelo Ramondo, Gennaro Santoro, Silvio Klugmann, Francesco Bedogni, Francesco Maisano, Antonio Marzocchi, Arnaldo Poli, Marco De Carlo, Massimo Napodano, Claudia Fiorina, Federico De Marco, David Antoniucci, Emanuela de Cillis, Davide Capodanno, Corrado Tamburino

The paucity of evidences about the long-term durability of currently available transcatheter prostheses is one of the main issues of transcatheter aortic valve implantation (TAVI). We sought to assess 3-year clinical and echocardiographic outcomes of patients undergoing TAVI with the third generation CoreValve prosthesis (Medtronic Incorporation, MN, USA). European Heart Journal (2012) 33, 969–976. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2012.

13 marzo 2012

JOURNAL OF CARDIOTHORACIC SURGERY. First case of transapical implantation of an aortic valve in a patient with dextrocardia

Hellmuth S vH Weich, Jacques van Wyk, Wynand van Zyl, Rocco Vivier, Andre Phillips and Thomas Mabin

We describe the clinical presentation and implantation procedure of the first transcatheter aortic valve implantation described in a patient with dextrocardia. Transcatheter aortic valve implantation is a relatively new technology where an aortic valve is implanted via a catheter [usually from the femoral artery]. It may also be implanted via a direct puncture of the left ventricular apex. We describe the first case of transcatheter aortic valve implantation [TAVI] in a patient with dextrocardia. ournal of Cardiothoracic Surgery 2012, 7:24. Copyright © 2012 vH Weich et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License

01 julio 2011

THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY. Transapical aortic valve implantation after previous mitral valve surgery

Thorsten Drews, MD, Miralem Pasic, MD, PhD, Semih Buz, MD, Axel Unbehaun, MD, Stephan Dreysse, MD, Marian Kukucka, MD, Alexander Mladenow, MD, and Roland Hetzer, MD, PhD

Transcatheter aortic valve implantation is a new method for treatment of very high-risk patients with aortic valve stenosis. Especially in patients who have had previous cardiac surgery, the operative risk can be reduced. Nevertheless, this new procedure has some potential risks in patients with previous mitral valve surgery, owing to the increased risk by direct contact between the 2 valves with inhibition of mechanical mitral leaflet mobility, in view of potential mitral annulus pressure or leaflet damage caused by transcatheter wires. The Journal of Thoracic and Cardiovascular Surgery. Volume 142, Number 1. Copyright ©
2011 by The American Association for Thoracic Surgery.